nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—ABCG2—Teniposide—lymphatic system cancer	0.139	0.19	CbGbCtD
Dabrafenib—ABCG2—Mitoxantrone—lymphatic system cancer	0.0974	0.133	CbGbCtD
Dabrafenib—SLCO1B3—Methotrexate—lymphatic system cancer	0.0877	0.12	CbGbCtD
Dabrafenib—ABCG2—Vincristine—lymphatic system cancer	0.067	0.0914	CbGbCtD
Dabrafenib—SLCO1B1—Methotrexate—lymphatic system cancer	0.0511	0.0697	CbGbCtD
Dabrafenib—SLC22A8—Methotrexate—lymphatic system cancer	0.0471	0.0643	CbGbCtD
Dabrafenib—ABCG2—Methotrexate—lymphatic system cancer	0.0406	0.0554	CbGbCtD
Dabrafenib—ABCB1—Mitoxantrone—lymphatic system cancer	0.0351	0.0479	CbGbCtD
Dabrafenib—SLC22A6—Methotrexate—lymphatic system cancer	0.0328	0.0448	CbGbCtD
Dabrafenib—CYP3A4—Cytarabine—lymphatic system cancer	0.0305	0.0417	CbGbCtD
Dabrafenib—CYP3A4—Teniposide—lymphatic system cancer	0.0301	0.041	CbGbCtD
Dabrafenib—ABCB1—Vincristine—lymphatic system cancer	0.0242	0.033	CbGbCtD
Dabrafenib—CYP3A4—Mitoxantrone—lymphatic system cancer	0.021	0.0287	CbGbCtD
Dabrafenib—ABCB1—Methotrexate—lymphatic system cancer	0.0146	0.02	CbGbCtD
Dabrafenib—CYP3A4—Vincristine—lymphatic system cancer	0.0145	0.0198	CbGbCtD
Dabrafenib—Hyperhidrosis—Teniposide—lymphatic system cancer	0.000707	0.00265	CcSEcCtD
Dabrafenib—Leukopenia—Fludarabine—lymphatic system cancer	0.000705	0.00264	CcSEcCtD
Dabrafenib—Haematuria—Bleomycin—lymphatic system cancer	0.000705	0.00264	CcSEcCtD
Dabrafenib—Pruritus—Mechlorethamine—lymphatic system cancer	0.000702	0.00263	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.000701	0.00262	CcSEcCtD
Dabrafenib—Cough—Fludarabine—lymphatic system cancer	0.000687	0.00257	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.000686	0.00257	CcSEcCtD
Dabrafenib—Hypotension—Teniposide—lymphatic system cancer	0.000684	0.00256	CcSEcCtD
Dabrafenib—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.000679	0.00254	CcSEcCtD
Dabrafenib—Neutropenia—Carmustine—lymphatic system cancer	0.000677	0.00253	CcSEcCtD
Dabrafenib—Myalgia—Fludarabine—lymphatic system cancer	0.000671	0.00251	CcSEcCtD
Dabrafenib—Arthralgia—Fludarabine—lymphatic system cancer	0.000671	0.00251	CcSEcCtD
Dabrafenib—Haemoglobin—Bleomycin—lymphatic system cancer	0.000667	0.0025	CcSEcCtD
Dabrafenib—Haemorrhage—Bleomycin—lymphatic system cancer	0.000663	0.00249	CcSEcCtD
Dabrafenib—Hyperglycaemia—Carmustine—lymphatic system cancer	0.000653	0.00244	CcSEcCtD
Dabrafenib—Neutropenia—Vincristine—lymphatic system cancer	0.000646	0.00242	CcSEcCtD
Dabrafenib—Oedema—Fludarabine—lymphatic system cancer	0.000643	0.00241	CcSEcCtD
Dabrafenib—Infection—Fludarabine—lymphatic system cancer	0.000639	0.00239	CcSEcCtD
Dabrafenib—Decreased appetite—Teniposide—lymphatic system cancer	0.000636	0.00238	CcSEcCtD
Dabrafenib—Renal failure—Carmustine—lymphatic system cancer	0.000634	0.00238	CcSEcCtD
Dabrafenib—Vomiting—Mechlorethamine—lymphatic system cancer	0.000631	0.00236	CcSEcCtD
Dabrafenib—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00063	0.00236	CcSEcCtD
Dabrafenib—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.000629	0.00236	CcSEcCtD
Dabrafenib—Neutropenia—Mitoxantrone—lymphatic system cancer	0.000629	0.00236	CcSEcCtD
Dabrafenib—Stomatitis—Carmustine—lymphatic system cancer	0.000629	0.00236	CcSEcCtD
Dabrafenib—Urinary tract infection—Carmustine—lymphatic system cancer	0.000627	0.00235	CcSEcCtD
Dabrafenib—Rash—Mechlorethamine—lymphatic system cancer	0.000626	0.00234	CcSEcCtD
Dabrafenib—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000625	0.00234	CcSEcCtD
Dabrafenib—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.000621	0.00233	CcSEcCtD
Dabrafenib—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.000607	0.00227	CcSEcCtD
Dabrafenib—Stomatitis—Vincristine—lymphatic system cancer	0.0006	0.00225	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000598	0.00224	CcSEcCtD
Dabrafenib—Chills—Bleomycin—lymphatic system cancer	0.000595	0.00223	CcSEcCtD
Dabrafenib—Bone disorder—Methotrexate—lymphatic system cancer	0.000591	0.00222	CcSEcCtD
Dabrafenib—Renal failure—Mitoxantrone—lymphatic system cancer	0.00059	0.00221	CcSEcCtD
Dabrafenib—Nausea—Mechlorethamine—lymphatic system cancer	0.000589	0.00221	CcSEcCtD
Dabrafenib—Hyperbilirubinaemia—Methotrexate—lymphatic system cancer	0.000587	0.0022	CcSEcCtD
Dabrafenib—Alopecia—Bleomycin—lymphatic system cancer	0.000586	0.0022	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000586	0.00219	CcSEcCtD
Dabrafenib—Stomatitis—Mitoxantrone—lymphatic system cancer	0.000585	0.00219	CcSEcCtD
Dabrafenib—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.000583	0.00218	CcSEcCtD
Dabrafenib—Haemoglobin—Carmustine—lymphatic system cancer	0.000582	0.00218	CcSEcCtD
Dabrafenib—Haemorrhage—Carmustine—lymphatic system cancer	0.000579	0.00217	CcSEcCtD
Dabrafenib—Abdominal pain—Teniposide—lymphatic system cancer	0.000578	0.00217	CcSEcCtD
Dabrafenib—Body temperature increased—Teniposide—lymphatic system cancer	0.000578	0.00217	CcSEcCtD
Dabrafenib—Erythema—Bleomycin—lymphatic system cancer	0.000578	0.00216	CcSEcCtD
Dabrafenib—Haematuria—Mitoxantrone—lymphatic system cancer	0.000572	0.00214	CcSEcCtD
Dabrafenib—Oedema peripheral—Carmustine—lymphatic system cancer	0.000571	0.00214	CcSEcCtD
Dabrafenib—Connective tissue disorder—Carmustine—lymphatic system cancer	0.000569	0.00213	CcSEcCtD
Dabrafenib—Decreased appetite—Fludarabine—lymphatic system cancer	0.000559	0.00209	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000555	0.00208	CcSEcCtD
Dabrafenib—Fatigue—Fludarabine—lymphatic system cancer	0.000554	0.00208	CcSEcCtD
Dabrafenib—Constipation—Fludarabine—lymphatic system cancer	0.00055	0.00206	CcSEcCtD
Dabrafenib—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000546	0.00204	CcSEcCtD
Dabrafenib—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000543	0.00203	CcSEcCtD
Dabrafenib—Urethral disorder—Vincristine—lymphatic system cancer	0.000542	0.00203	CcSEcCtD
Dabrafenib—Eye disorder—Carmustine—lymphatic system cancer	0.000541	0.00203	CcSEcCtD
Dabrafenib—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000541	0.00203	CcSEcCtD
Dabrafenib—Hypersensitivity—Teniposide—lymphatic system cancer	0.000539	0.00202	CcSEcCtD
Dabrafenib—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.000538	0.00202	CcSEcCtD
Dabrafenib—Anaemia—Bleomycin—lymphatic system cancer	0.000534	0.002	CcSEcCtD
Dabrafenib—Asthenia—Teniposide—lymphatic system cancer	0.000525	0.00197	CcSEcCtD
Dabrafenib—Pruritus—Teniposide—lymphatic system cancer	0.000518	0.00194	CcSEcCtD
Dabrafenib—Arrhythmia—Carmustine—lymphatic system cancer	0.000517	0.00194	CcSEcCtD
Dabrafenib—Leukopenia—Bleomycin—lymphatic system cancer	0.000517	0.00194	CcSEcCtD
Dabrafenib—Alopecia—Carmustine—lymphatic system cancer	0.000512	0.00192	CcSEcCtD
Dabrafenib—Body temperature increased—Fludarabine—lymphatic system cancer	0.000508	0.0019	CcSEcCtD
Dabrafenib—Mental disorder—Carmustine—lymphatic system cancer	0.000507	0.0019	CcSEcCtD
Dabrafenib—Erythema—Carmustine—lymphatic system cancer	0.000504	0.00189	CcSEcCtD
Dabrafenib—Malnutrition—Carmustine—lymphatic system cancer	0.000504	0.00189	CcSEcCtD
Dabrafenib—Cough—Bleomycin—lymphatic system cancer	0.000504	0.00189	CcSEcCtD
Dabrafenib—Angiopathy—Vincristine—lymphatic system cancer	0.000502	0.00188	CcSEcCtD
Dabrafenib—Diarrhoea—Teniposide—lymphatic system cancer	0.0005	0.00187	CcSEcCtD
Dabrafenib—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000498	0.00187	CcSEcCtD
Dabrafenib—Myalgia—Bleomycin—lymphatic system cancer	0.000492	0.00184	CcSEcCtD
Dabrafenib—Alopecia—Vincristine—lymphatic system cancer	0.000489	0.00183	CcSEcCtD
Dabrafenib—Back pain—Carmustine—lymphatic system cancer	0.000488	0.00183	CcSEcCtD
Dabrafenib—Mental disorder—Vincristine—lymphatic system cancer	0.000484	0.00181	CcSEcCtD
Dabrafenib—Chills—Mitoxantrone—lymphatic system cancer	0.000483	0.00181	CcSEcCtD
Dabrafenib—Neoplasm—Methotrexate—lymphatic system cancer	0.000483	0.00181	CcSEcCtD
Dabrafenib—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000481	0.0018	CcSEcCtD
Dabrafenib—Alopecia—Mitoxantrone—lymphatic system cancer	0.000476	0.00178	CcSEcCtD
Dabrafenib—Vision blurred—Carmustine—lymphatic system cancer	0.000475	0.00178	CcSEcCtD
Dabrafenib—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000474	0.00177	CcSEcCtD
Dabrafenib—Oedema—Bleomycin—lymphatic system cancer	0.000471	0.00177	CcSEcCtD
Dabrafenib—Erythema—Mitoxantrone—lymphatic system cancer	0.000469	0.00176	CcSEcCtD
Dabrafenib—Infection—Bleomycin—lymphatic system cancer	0.000468	0.00175	CcSEcCtD
Dabrafenib—Anaemia—Carmustine—lymphatic system cancer	0.000466	0.00175	CcSEcCtD
Dabrafenib—Back pain—Vincristine—lymphatic system cancer	0.000466	0.00174	CcSEcCtD
Dabrafenib—Vomiting—Teniposide—lymphatic system cancer	0.000465	0.00174	CcSEcCtD
Dabrafenib—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000462	0.00173	CcSEcCtD
Dabrafenib—Asthenia—Fludarabine—lymphatic system cancer	0.000461	0.00173	CcSEcCtD
Dabrafenib—Rash—Teniposide—lymphatic system cancer	0.000461	0.00173	CcSEcCtD
Dabrafenib—Dermatitis—Teniposide—lymphatic system cancer	0.000461	0.00173	CcSEcCtD
Dabrafenib—Headache—Teniposide—lymphatic system cancer	0.000458	0.00172	CcSEcCtD
Dabrafenib—Pruritus—Fludarabine—lymphatic system cancer	0.000455	0.0017	CcSEcCtD
Dabrafenib—Back pain—Mitoxantrone—lymphatic system cancer	0.000453	0.0017	CcSEcCtD
Dabrafenib—Leukopenia—Carmustine—lymphatic system cancer	0.000451	0.00169	CcSEcCtD
Dabrafenib—Anaemia—Vincristine—lymphatic system cancer	0.000445	0.00167	CcSEcCtD
Dabrafenib—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000442	0.00165	CcSEcCtD
Dabrafenib—Hypotension—Bleomycin—lymphatic system cancer	0.00044	0.00165	CcSEcCtD
Dabrafenib—Diarrhoea—Fludarabine—lymphatic system cancer	0.00044	0.00165	CcSEcCtD
Dabrafenib—Hypertension—Carmustine—lymphatic system cancer	0.000435	0.00163	CcSEcCtD
Dabrafenib—Nausea—Teniposide—lymphatic system cancer	0.000434	0.00163	CcSEcCtD
Dabrafenib—Anaemia—Mitoxantrone—lymphatic system cancer	0.000433	0.00162	CcSEcCtD
Dabrafenib—Leukopenia—Vincristine—lymphatic system cancer	0.000431	0.00161	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000429	0.00161	CcSEcCtD
Dabrafenib—Myalgia—Carmustine—lymphatic system cancer	0.000429	0.00161	CcSEcCtD
Dabrafenib—Renal failure acute—Methotrexate—lymphatic system cancer	0.00042	0.00157	CcSEcCtD
Dabrafenib—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00042	0.00157	CcSEcCtD
Dabrafenib—Hypertension—Vincristine—lymphatic system cancer	0.000415	0.00156	CcSEcCtD
Dabrafenib—Oedema—Carmustine—lymphatic system cancer	0.000411	0.00154	CcSEcCtD
Dabrafenib—Decreased appetite—Bleomycin—lymphatic system cancer	0.00041	0.00153	CcSEcCtD
Dabrafenib—Myalgia—Vincristine—lymphatic system cancer	0.00041	0.00153	CcSEcCtD
Dabrafenib—Cough—Mitoxantrone—lymphatic system cancer	0.000409	0.00153	CcSEcCtD
Dabrafenib—Infection—Carmustine—lymphatic system cancer	0.000409	0.00153	CcSEcCtD
Dabrafenib—Vomiting—Fludarabine—lymphatic system cancer	0.000409	0.00153	CcSEcCtD
Dabrafenib—Rash—Fludarabine—lymphatic system cancer	0.000405	0.00152	CcSEcCtD
Dabrafenib—Dermatitis—Fludarabine—lymphatic system cancer	0.000405	0.00152	CcSEcCtD
Dabrafenib—Hypertension—Mitoxantrone—lymphatic system cancer	0.000405	0.00152	CcSEcCtD
Dabrafenib—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000403	0.00151	CcSEcCtD
Dabrafenib—Headache—Fludarabine—lymphatic system cancer	0.000403	0.00151	CcSEcCtD
Dabrafenib—Myalgia—Mitoxantrone—lymphatic system cancer	0.000399	0.00149	CcSEcCtD
Dabrafenib—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000399	0.00149	CcSEcCtD
Dabrafenib—Oedema—Vincristine—lymphatic system cancer	0.000393	0.00147	CcSEcCtD
Dabrafenib—Infection—Vincristine—lymphatic system cancer	0.00039	0.00146	CcSEcCtD
Dabrafenib—Nervous system disorder—Vincristine—lymphatic system cancer	0.000385	0.00144	CcSEcCtD
Dabrafenib—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000385	0.00144	CcSEcCtD
Dabrafenib—Hypotension—Carmustine—lymphatic system cancer	0.000384	0.00144	CcSEcCtD
Dabrafenib—Oedema—Mitoxantrone—lymphatic system cancer	0.000383	0.00143	CcSEcCtD
Dabrafenib—Nausea—Fludarabine—lymphatic system cancer	0.000382	0.00143	CcSEcCtD
Dabrafenib—Infection—Mitoxantrone—lymphatic system cancer	0.00038	0.00142	CcSEcCtD
Dabrafenib—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00038	0.00142	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000375	0.0014	CcSEcCtD
Dabrafenib—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000375	0.0014	CcSEcCtD
Dabrafenib—Body temperature increased—Bleomycin—lymphatic system cancer	0.000373	0.0014	CcSEcCtD
Dabrafenib—Insomnia—Carmustine—lymphatic system cancer	0.000372	0.00139	CcSEcCtD
Dabrafenib—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000372	0.00139	CcSEcCtD
Dabrafenib—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00037	0.00139	CcSEcCtD
Dabrafenib—Hypotension—Vincristine—lymphatic system cancer	0.000367	0.00137	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000358	0.00134	CcSEcCtD
Dabrafenib—Decreased appetite—Carmustine—lymphatic system cancer	0.000358	0.00134	CcSEcCtD
Dabrafenib—Hypotension—Mitoxantrone—lymphatic system cancer	0.000357	0.00134	CcSEcCtD
Dabrafenib—Insomnia—Vincristine—lymphatic system cancer	0.000355	0.00133	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000355	0.00133	CcSEcCtD
Dabrafenib—Constipation—Carmustine—lymphatic system cancer	0.000352	0.00132	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000348	0.00131	CcSEcCtD
Dabrafenib—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000347	0.0013	CcSEcCtD
Dabrafenib—Decreased appetite—Vincristine—lymphatic system cancer	0.000341	0.00128	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000339	0.00127	CcSEcCtD
Dabrafenib—Fatigue—Vincristine—lymphatic system cancer	0.000339	0.00127	CcSEcCtD
Dabrafenib—Asthenia—Bleomycin—lymphatic system cancer	0.000338	0.00127	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000336	0.00126	CcSEcCtD
Dabrafenib—Constipation—Vincristine—lymphatic system cancer	0.000336	0.00126	CcSEcCtD
Dabrafenib—Pruritus—Bleomycin—lymphatic system cancer	0.000333	0.00125	CcSEcCtD
Dabrafenib—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000333	0.00125	CcSEcCtD
Dabrafenib—Fatigue—Mitoxantrone—lymphatic system cancer	0.00033	0.00124	CcSEcCtD
Dabrafenib—Pancreatitis—Methotrexate—lymphatic system cancer	0.000329	0.00123	CcSEcCtD
Dabrafenib—Constipation—Mitoxantrone—lymphatic system cancer	0.000327	0.00123	CcSEcCtD
Dabrafenib—Abdominal pain—Carmustine—lymphatic system cancer	0.000325	0.00122	CcSEcCtD
Dabrafenib—Body temperature increased—Carmustine—lymphatic system cancer	0.000325	0.00122	CcSEcCtD
Dabrafenib—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000321	0.0012	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000321	0.0012	CcSEcCtD
Dabrafenib—Neutropenia—Methotrexate—lymphatic system cancer	0.000313	0.00117	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000313	0.00117	CcSEcCtD
Dabrafenib—Abdominal pain—Vincristine—lymphatic system cancer	0.00031	0.00116	CcSEcCtD
Dabrafenib—Body temperature increased—Vincristine—lymphatic system cancer	0.00031	0.00116	CcSEcCtD
Dabrafenib—Hypersensitivity—Carmustine—lymphatic system cancer	0.000303	0.00114	CcSEcCtD
Dabrafenib—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000302	0.00113	CcSEcCtD
Dabrafenib—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000302	0.00113	CcSEcCtD
Dabrafenib—Vomiting—Bleomycin—lymphatic system cancer	0.0003	0.00112	CcSEcCtD
Dabrafenib—Infestation NOS—Methotrexate—lymphatic system cancer	0.000299	0.00112	CcSEcCtD
Dabrafenib—Infestation—Methotrexate—lymphatic system cancer	0.000299	0.00112	CcSEcCtD
Dabrafenib—Rash—Bleomycin—lymphatic system cancer	0.000297	0.00111	CcSEcCtD
Dabrafenib—Dermatitis—Bleomycin—lymphatic system cancer	0.000297	0.00111	CcSEcCtD
Dabrafenib—Asthenia—Carmustine—lymphatic system cancer	0.000295	0.00111	CcSEcCtD
Dabrafenib—Renal failure—Methotrexate—lymphatic system cancer	0.000294	0.0011	CcSEcCtD
Dabrafenib—Stomatitis—Methotrexate—lymphatic system cancer	0.000291	0.00109	CcSEcCtD
Dabrafenib—Hypersensitivity—Vincristine—lymphatic system cancer	0.000289	0.00108	CcSEcCtD
Dabrafenib—Haematuria—Methotrexate—lymphatic system cancer	0.000285	0.00107	CcSEcCtD
Dabrafenib—Epistaxis—Methotrexate—lymphatic system cancer	0.000282	0.00106	CcSEcCtD
Dabrafenib—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000282	0.00106	CcSEcCtD
Dabrafenib—Asthenia—Vincristine—lymphatic system cancer	0.000282	0.00106	CcSEcCtD
Dabrafenib—Diarrhoea—Carmustine—lymphatic system cancer	0.000282	0.00105	CcSEcCtD
Dabrafenib—Nausea—Bleomycin—lymphatic system cancer	0.00028	0.00105	CcSEcCtD
Dabrafenib—Asthenia—Mitoxantrone—lymphatic system cancer	0.000274	0.00103	CcSEcCtD
Dabrafenib—Dizziness—Carmustine—lymphatic system cancer	0.000272	0.00102	CcSEcCtD
Dabrafenib—Haemoglobin—Methotrexate—lymphatic system cancer	0.00027	0.00101	CcSEcCtD
Dabrafenib—Diarrhoea—Vincristine—lymphatic system cancer	0.000269	0.00101	CcSEcCtD
Dabrafenib—Haemorrhage—Methotrexate—lymphatic system cancer	0.000268	0.001	CcSEcCtD
Dabrafenib—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000265	0.000992	CcSEcCtD
Dabrafenib—Urethral disorder—Methotrexate—lymphatic system cancer	0.000263	0.000985	CcSEcCtD
Dabrafenib—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000262	0.00098	CcSEcCtD
Dabrafenib—Vomiting—Carmustine—lymphatic system cancer	0.000262	0.00098	CcSEcCtD
Dabrafenib—Dizziness—Vincristine—lymphatic system cancer	0.00026	0.000973	CcSEcCtD
Dabrafenib—Rash—Carmustine—lymphatic system cancer	0.000259	0.000972	CcSEcCtD
Dabrafenib—Dermatitis—Carmustine—lymphatic system cancer	0.000259	0.000971	CcSEcCtD
Dabrafenib—Headache—Carmustine—lymphatic system cancer	0.000258	0.000965	CcSEcCtD
Dabrafenib—Eye disorder—Methotrexate—lymphatic system cancer	0.000251	0.000939	CcSEcCtD
Dabrafenib—Vomiting—Vincristine—lymphatic system cancer	0.00025	0.000935	CcSEcCtD
Dabrafenib—Rash—Vincristine—lymphatic system cancer	0.000248	0.000928	CcSEcCtD
Dabrafenib—Dermatitis—Vincristine—lymphatic system cancer	0.000247	0.000927	CcSEcCtD
Dabrafenib—Headache—Vincristine—lymphatic system cancer	0.000246	0.000922	CcSEcCtD
Dabrafenib—Nausea—Carmustine—lymphatic system cancer	0.000244	0.000915	CcSEcCtD
Dabrafenib—Angiopathy—Methotrexate—lymphatic system cancer	0.000243	0.000912	CcSEcCtD
Dabrafenib—Vomiting—Mitoxantrone—lymphatic system cancer	0.000243	0.000911	CcSEcCtD
Dabrafenib—Immune system disorder—Methotrexate—lymphatic system cancer	0.000242	0.000908	CcSEcCtD
Dabrafenib—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000242	0.000906	CcSEcCtD
Dabrafenib—Rash—Mitoxantrone—lymphatic system cancer	0.000241	0.000903	CcSEcCtD
Dabrafenib—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000241	0.000903	CcSEcCtD
Dabrafenib—Chills—Methotrexate—lymphatic system cancer	0.000241	0.000902	CcSEcCtD
Dabrafenib—Headache—Mitoxantrone—lymphatic system cancer	0.00024	0.000898	CcSEcCtD
Dabrafenib—Alopecia—Methotrexate—lymphatic system cancer	0.000237	0.000888	CcSEcCtD
Dabrafenib—Mental disorder—Methotrexate—lymphatic system cancer	0.000235	0.00088	CcSEcCtD
Dabrafenib—Malnutrition—Methotrexate—lymphatic system cancer	0.000234	0.000875	CcSEcCtD
Dabrafenib—Erythema—Methotrexate—lymphatic system cancer	0.000234	0.000875	CcSEcCtD
Dabrafenib—Nausea—Vincristine—lymphatic system cancer	0.000233	0.000874	CcSEcCtD
Dabrafenib—Nausea—Mitoxantrone—lymphatic system cancer	0.000227	0.000851	CcSEcCtD
Dabrafenib—Back pain—Methotrexate—lymphatic system cancer	0.000226	0.000846	CcSEcCtD
Dabrafenib—Vision blurred—Methotrexate—lymphatic system cancer	0.00022	0.000824	CcSEcCtD
Dabrafenib—Anaemia—Methotrexate—lymphatic system cancer	0.000216	0.000808	CcSEcCtD
Dabrafenib—Leukopenia—Methotrexate—lymphatic system cancer	0.000209	0.000783	CcSEcCtD
Dabrafenib—Cough—Methotrexate—lymphatic system cancer	0.000204	0.000763	CcSEcCtD
Dabrafenib—Myalgia—Methotrexate—lymphatic system cancer	0.000199	0.000745	CcSEcCtD
Dabrafenib—Arthralgia—Methotrexate—lymphatic system cancer	0.000199	0.000745	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000197	0.00074	CcSEcCtD
Dabrafenib—Infection—Methotrexate—lymphatic system cancer	0.000189	0.000709	CcSEcCtD
Dabrafenib—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000187	0.0007	CcSEcCtD
Dabrafenib—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000187	0.000699	CcSEcCtD
Dabrafenib—Skin disorder—Methotrexate—lymphatic system cancer	0.000185	0.000693	CcSEcCtD
Dabrafenib—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000184	0.00069	CcSEcCtD
Dabrafenib—Hypotension—Methotrexate—lymphatic system cancer	0.000178	0.000667	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000174	0.00065	CcSEcCtD
Dabrafenib—Insomnia—Methotrexate—lymphatic system cancer	0.000172	0.000646	CcSEcCtD
Dabrafenib—Decreased appetite—Methotrexate—lymphatic system cancer	0.000166	0.000621	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000165	0.000616	CcSEcCtD
Dabrafenib—Fatigue—Methotrexate—lymphatic system cancer	0.000164	0.000615	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000156	0.000584	CcSEcCtD
Dabrafenib—Abdominal pain—Methotrexate—lymphatic system cancer	0.000151	0.000564	CcSEcCtD
Dabrafenib—Body temperature increased—Methotrexate—lymphatic system cancer	0.000151	0.000564	CcSEcCtD
Dabrafenib—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00014	0.000526	CcSEcCtD
Dabrafenib—Asthenia—Methotrexate—lymphatic system cancer	0.000137	0.000512	CcSEcCtD
Dabrafenib—Pruritus—Methotrexate—lymphatic system cancer	0.000135	0.000505	CcSEcCtD
Dabrafenib—Diarrhoea—Methotrexate—lymphatic system cancer	0.00013	0.000488	CcSEcCtD
Dabrafenib—Dizziness—Methotrexate—lymphatic system cancer	0.000126	0.000472	CcSEcCtD
Dabrafenib—Vomiting—Methotrexate—lymphatic system cancer	0.000121	0.000454	CcSEcCtD
Dabrafenib—Rash—Methotrexate—lymphatic system cancer	0.00012	0.00045	CcSEcCtD
Dabrafenib—Dermatitis—Methotrexate—lymphatic system cancer	0.00012	0.00045	CcSEcCtD
Dabrafenib—Headache—Methotrexate—lymphatic system cancer	0.000119	0.000447	CcSEcCtD
Dabrafenib—Nausea—Methotrexate—lymphatic system cancer	0.000113	0.000424	CcSEcCtD
